A detailed history of Cwm, LLC transactions in Vaxart, Inc. stock. As of the latest transaction made, Cwm, LLC holds 10 shares of VXRT stock, worth $6. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10
Holding current value
$6
% of portfolio
0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$0.58 - $0.99 $5 - $9
10 New
10 $0
Q2 2022

Jul 28, 2022

BUY
$2.7 - $5.28 $270 - $528
100 New
100 $0
Q1 2022

Apr 21, 2022

SELL
$4.29 - $6.64 $1,716 - $2,656
-400 Closed
0 $0
Q4 2021

Jan 31, 2022

SELL
$5.77 - $7.96 $9,232 - $12,736
-1,600 Reduced 80.0%
400 $3,000
Q4 2020

Sep 15, 2021

BUY
$3.5 - $7.98 $7,000 - $15,960
2,000 New
2,000 $15,000
Q4 2020

Jan 27, 2021

SELL
$3.5 - $7.98 $7,000 - $15,960
-2,000 Closed
0 $0
Q3 2020

Sep 15, 2021

BUY
$4.78 - $16.97 $9,560 - $33,940
2,000 New
2,000 $15,000
Q3 2020

Oct 19, 2020

SELL
$4.78 - $16.97 $9,560 - $33,940
-2,000 Closed
0 $0
Q2 2020

Sep 15, 2021

BUY
$1.68 - $8.85 $3,360 - $17,700
2,000 New
2,000 $15,000
Q2 2020

Jul 22, 2020

SELL
$1.68 - $8.85 $3,360 - $17,700
-2,000 Closed
0 $0
Q1 2020

Sep 15, 2021

BUY
$0.34 - $2.87 $680 - $5,740
2,000 New
2,000 $15,000
Q1 2020

Apr 28, 2020

SELL
$0.34 - $2.87 $680 - $5,740
-2,000 Closed
0 $0
Q4 2019

Sep 14, 2021

BUY
$0.28 - $0.39 $560 - $780
2,000 New
2,000 $15,000
Q4 2019

Jan 27, 2020

SELL
$0.28 - $0.39 $560 - $780
-2,000 Closed
0 $0
Q3 2019

Sep 14, 2021

BUY
$0.3 - $0.75 $600 - $1,500
2,000 New
2,000 $15,000
Q3 2019

Oct 22, 2019

SELL
$0.3 - $0.75 $600 - $1,500
-2,000 Closed
0 $0
Q2 2019

Sep 14, 2021

BUY
$0.63 - $2.04 $1,260 - $4,080
2,000 New
2,000 $15,000
Q2 2019

Jul 31, 2019

SELL
$0.63 - $2.04 $1,260 - $4,080
-2,000 Closed
0 $0
Q1 2019

Sep 02, 2021

BUY
$1.5 - $2.34 $3,000 - $4,680
2,000 New
2,000 $0

Others Institutions Holding VXRT

About Vaxart, Inc.


  • Ticker VXRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,506,000
  • Market Cap $77.2M
  • Description
  • Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...
More about VXRT
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.